Rep. Jared Moskowitz Buys AbbVie Inc. (NYSE:ABBV) Stock

Representative Jared Moskowitz (D-Florida) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on May 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in AbbVie stock on April 7th. The trade occurred in the Representative’s “MORGAN STANLEY ACTIVE ASSETS (1)” account.

Representative Jared Moskowitz also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 4/16/2025.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 4/16/2025.
• Sold $1,001 – $15,000 in shares of Starbucks (NASDAQ:SBUX) on 4/10/2025.
• Sold $15,001 – $50,000 in shares of The Goldman Sachs Group (NYSE:GS) on 4/10/2025.
• Sold $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 4/10/2025.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 4/7/2025.
• Purchased $1,001 – $15,000 in shares of Southern (NYSE:SO) on 4/7/2025.
• Purchased $1,001 – $15,000 in shares of Sherwin-Williams (NYSE:SHW) on 4/7/2025.
• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 4/7/2025.
• Purchased $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 4/7/2025.

AbbVie Stock Performance

Shares of AbbVie stock traded down $2.75 during trading hours on Tuesday, hitting $187.32. 1,758,818 shares of the company’s stock traded hands, compared to its average volume of 6,143,701. The company has a fifty day simple moving average of $193.79 and a 200-day simple moving average of $187.23. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. The stock has a market capitalization of $331.36 billion, a price-to-earnings ratio of 78.05, a PEG ratio of 1.62 and a beta of 0.56. AbbVie Inc. has a 12-month low of $153.58 and a 12-month high of $218.66.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.40 by $0.06. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The firm had revenue of $13.34 billion for the quarter, compared to analysts’ expectations of $12.91 billion. During the same period in the previous year, the company earned $2.31 earnings per share. The company’s quarterly revenue was up 8.4% on a year-over-year basis. Equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be paid a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.50%. AbbVie’s dividend payout ratio (DPR) is presently 279.15%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company boosted their price objective on AbbVie from $210.00 to $240.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. UBS Group lifted their price objective on shares of AbbVie from $181.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Raymond James reaffirmed an “outperform” rating and issued a $220.00 price target (up from $218.00) on shares of AbbVie in a report on Monday, February 3rd. Guggenheim increased their price objective on AbbVie from $214.00 to $216.00 and gave the stock a “buy” rating in a report on Tuesday, April 29th. Finally, BNP Paribas raised AbbVie to a “hold” rating in a report on Thursday, May 8th. Seven research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $211.41.

Insiders Place Their Bets

In other news, EVP Timothy J. Richmond sold 29,917 shares of the stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the transaction, the executive vice president now directly owns 44,284 shares of the company’s stock, valued at $8,985,223.60. This represents a 40.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Perry C. Siatis sold 5,778 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $197.90, for a total value of $1,143,466.20. Following the completion of the transaction, the executive vice president now owns 22,381 shares in the company, valued at approximately $4,429,199.90. This trade represents a 20.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 113,471 shares of company stock valued at $23,426,451. Insiders own 0.25% of the company’s stock.

Hedge Funds Weigh In On AbbVie

Large investors have recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its holdings in AbbVie by 12.3% in the third quarter. Principal Financial Group Inc. now owns 2,487,363 shares of the company’s stock worth $491,204,000 after acquiring an additional 273,078 shares in the last quarter. Watts Gwilliam & Co. LLC raised its position in shares of AbbVie by 0.4% in the 4th quarter. Watts Gwilliam & Co. LLC now owns 16,186 shares of the company’s stock worth $2,906,000 after purchasing an additional 70 shares during the last quarter. Fortitude Family Office LLC boosted its stake in AbbVie by 0.9% in the 4th quarter. Fortitude Family Office LLC now owns 10,350 shares of the company’s stock worth $1,839,000 after purchasing an additional 91 shares in the last quarter. Baker Tilly Wealth Management LLC grew its position in AbbVie by 2.5% during the 4th quarter. Baker Tilly Wealth Management LLC now owns 3,890 shares of the company’s stock valued at $691,000 after purchasing an additional 94 shares during the last quarter. Finally, ORG Partners LLC increased its stake in AbbVie by 26.5% during the 4th quarter. ORG Partners LLC now owns 12,096 shares of the company’s stock valued at $2,155,000 after purchasing an additional 2,535 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida’s 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 23rd Congressional District. He declared candidacy for the 2026 election.

Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor’s degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz’s career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.